超声引导下注射聚桂醇硬化治疗肝肾囊肿的临床效果

Clinical effect of sclerotherapy by ultrasound-guided injection of lauromacrogol for hepatic and renal cysts

目的探讨超声引导下注射聚桂醇硬化治疗肝肾囊肿的疗效及其不良反应。方法对68例肝肾囊肿患者(69个囊肿)在超声引导下注射聚桂醇硬化治疗,术后1、3、6个月随访期间观察囊肿体积的变化及疗效。结果68例患者均穿刺成功。1月后复查全部囊肿均缩小50%以上,3月后27个囊肿消失,6月后65个消失或几乎消失。本组囊肿治疗有效率为100.0%,治愈率为94.2%。63例患者无明显不良反应,其余5例中,其中3例患者术后有轻微灼烧感,2例患者出现术后低热反应。结论聚桂醇作为肝肾囊肿硬化治疗的一种新型硬化剂,治愈率高,疗效确切,且不良反应较少。

Objective To investigate the efficacy and adverse reactions of ultrasound-guided injection of lauromacrogol in the treatment of hepatorenal cyst. Methods A total of 68 patients (69 cysts) with hepatorenal cyst were treated with sclerotherapy by ultrasound-guided injection of lauromacrogol. Changes in cyst volume and its efficacy during follow-up at 1, 3, and 6 months after surgery were observed. Results All the 68 patients were successfully punctured, and all the cysts were reduced by more than 50% after 1 month. A total of 27 cysts disappeared after 3 months of treatment, and 65 disappeared or nearly disappeared after 6 months. The effective rate was 100.0% and the cure rate was 94.2%. There were no obvious adverse reactions in 63 patients. Out of the rest 5 patients, mild burning sensation occurred in 3 patients and low postoperative fever in 2 patients. Conclusion Lauromacrogol, as a new type of hardeners for hepatorenal cyst, had significantly lower adverse reactions, better cure rate and definite curative efficacy.